# SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation

Study · id `cardio:ct-nct07445789` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07445789](<https://clinicaltrials.gov/study/NCT07445789>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07445789

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 436 participants.

## Technical summary

Registry record NCT07445789. Randomized; quadruple masking; primary purpose treatment. Start 2026-06 (anticipated); primary completion 2029-06 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 436 participants (planned count; ClinicalTrials.gov record NCT07445789, source copy `cardio:ctgov-nct07445789-2026-03-27`, retrieved 2026-10-26)
- Planned start: 2026-06 (anticipated) (ClinicalTrials.gov record NCT07445789, source copy `cardio:ctgov-nct07445789-2026-03-27`, retrieved 2026-10-26)
- Primary completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT07445789, source copy `cardio:ctgov-nct07445789-2026-03-27`, retrieved 2026-10-26)
- Completion: 2029-06 (anticipated) (ClinicalTrials.gov record NCT07445789, source copy `cardio:ctgov-nct07445789-2026-03-27`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07445789-2026-03-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: SMART-VERAPAF: Self-MAnagement and Random Therapy With VERApamil or Metoprolol in Paroxysmal Atrial Fibrillation
- Acronym: SMART-VERAPAF
- Condition: Atrial Fibrillation (AF)
- Intervention (Drug): Verapamil 240 mg slow-release tablet
- Intervention (Drug): metoprolol 100 mg slow-release tablet
- Lead sponsor: Martini Hospital Groningen
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)

## Provenance

Content hash: 7672975258b7a651327d785bdc2213777f79d67ddf2ad227a2ad95e1dff4baf5
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
